Morphea
Basics
Description
- A benign inflammatory skin disorder leading to excessive collagen deposition with thickening and sclerosis of the skin and subcutaneous tissues with characteristic plaque formation
- Lesions are well circumscribed, flat, firm to touch, and have a waxy feel. They may be more easily felt than seen, and in initial presentation, itching may occur. They are ivory colored and have a lilac or erythematous halo border.
- Lesions are not associated with systemic sclerosis (scleroderma) based on lack of sclerosis of fingertips (sclerodactyly), Raynaud phenomenon, and nail fold capillary changes.
- Three phases: active/edematous, inactive/sclerotic/fibrotic, and atrophic lesions
- Morphea is classified into five types (Mayo classification):
- Plaque: most common subtype especially in adults, well circumscribed, and confined to dermis
- Generalized: 4+ plaques involving 2+ body sites
- Bullous: rare
- Linear: most common subtype in children
- Deep: more severe and involving all layers from skin to bone, causing limb contractures and muscle atrophy
- Synonym(s): localized scleroderma (LS); scleroderma circumscripta
Epidemiology
Incidence
- Predominant sex: female > male (2.4 to 5:1)
- Peak incidence of plaque subtype in 3rd to 4th decade
- 50% of morphea cases present during childhood.
- Linear morphea can develop before age 10 years in 20% of patients.
- 0.3 to 3.0 cases per 100,000/year
Prevalence
- Onset in children is between ages 2 and 14 years.
- 50 cases per 100,000 at age 18 years
- 220 cases per 100,000 at age 80 years
Etiology and Pathophysiology
- Sclerosis is limited to the skin and systemic sclerosis is absent.
- Biopsy shows lymphocytic perivascular infiltration of the dermis, decreased number of blood vessels, and eccrine (sweat) glands.
- Causation thought to be from vascular damage and enhanced collagen production, although likely with underlying autoimmune etiology
- Drug-induced morphea primarily identified in association with TNF-α inhibitors
- Some association with past trauma, including surgery and vaccination administration, or radiation to the area
Risk Factors
Unknown. Presence of Raynaud phenomenon is a risk factor or marker for possible systemic sclerosis (scleroderma).
Commonly Associated Conditions
- Occurs with slightly greater frequency in those with a personal or family history of autoimmune disorders
- Sometimes associated with other diagnosis, such as arthralgias, carpal tunnel syndrome, Raynaud phenomenon, spina bifida, lichen planus, lichen sclerosis, vitiligo, and alopecia areata
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Domino, Frank J., et al., editors. "Morphea." 5-Minute Clinical Consult, 33rd ed., Wolters Kluwer, 2025. Medicine Central, im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/816329/all/Morphea.
Morphea. In: Domino FJF, Baldor RAR, Golding JJ, et al, eds. 5-Minute Clinical Consult. Wolters Kluwer; 2025. https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/816329/all/Morphea. Accessed November 24, 2024.
Morphea. (2025). In Domino, F. J., Baldor, R. A., Golding, J., & Stephens, M. B. (Eds.), 5-Minute Clinical Consult (33rd ed.). Wolters Kluwer. https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/816329/all/Morphea
Morphea [Internet]. In: Domino FJF, Baldor RAR, Golding JJ, Stephens MBM, editors. 5-Minute Clinical Consult. Wolters Kluwer; 2025. [cited 2024 November 24]. Available from: https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/816329/all/Morphea.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Morphea
ID - 816329
ED - Domino,Frank J,
ED - Baldor,Robert A,
ED - Golding,Jeremy,
ED - Stephens,Mark B,
BT - 5-Minute Clinical Consult, Updating
UR - https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/816329/all/Morphea
PB - Wolters Kluwer
ET - 33
DB - Medicine Central
DP - Unbound Medicine
ER -